rFSH SC Injection 150IU

✔️ Overdose Effects

Excessive doses of rFSH can cause ovarian hyperstimulation in women. The severity depends on the dose and individual response. Suspected overdose or symptoms of ovarian hyperstimulation require prompt medical assessment.

✔️ Dosage & Administration

rFSH is generally administered by slow subcutaneous injection. Injection sites should be rotated to reduce the risk of local tissue changes, and any unused solution should be discarded. Self-administration may be considered only after proper training and under medical guidance.

Dosage in Women

The dose varies considerably between individuals and must be adjusted according to ovarian response. Ultrasound examinations and serum estradiol measurements are required to monitor follicular development and minimize the risk of ovarian hyperstimulation. rFSH may be used alone or with a gonadotropin-releasing hormone (GnRH) analogue, depending on the treatment protocol.

Ovulation Induction

A typical starting dose is 75 IU subcutaneously once daily for at least seven days. Depending on follicular growth and estradiol levels, the dose may be increased gradually under medical supervision. Once appropriate follicular development is achieved, hCG may be administered to trigger final oocyte maturation and ovulation.

Assisted Reproductive Technology (ART)

The usual starting dose may range from 150 to 300 IU daily for at least the first four days. Subsequent doses are adjusted according to ultrasound findings and estradiol levels. When follicular development is adequate, hCG may be given to trigger final oocyte maturation. Egg retrieval is generally performed 34–36 hours after the hCG injection.

PCOS-Related Infertility

Treatment commonly begins with a low daily dose, often 75 IU, administered subcutaneously. The dose and duration are adjusted according to the individual's ovarian response, assessed through hormone measurements and ultrasound monitoring. Increases must be made cautiously to reduce the risk of ovarian hyperstimulation.

Dosage in Men

For men with hypogonadotropic hypogonadism, rFSH is used with hCG to stimulate sperm production. hCG is generally administered first to achieve appropriate testosterone levels, after which rFSH may be added. Treatment doses and follow-up should be determined by a specialist, with semen analysis commonly performed after four to six months to assess response.

The doses above are general reference information, not a self-treatment schedule. rFSH treatment requires specialist supervision and monitoring.

✔️ Recnsitution

For a 75 IU vial, the supplied instructions may specify dissolving the powder in 1 mL of water for injection. Gently swirl the vial until the solution becomes clear; do not shake vigorously. Do not use the solution if it contains particles or appears cloudy.

If multiple vials are required, reconstitution and transfer must follow the exact product instructions and be performed using proper sterile technique by a trained healthcare professional. The appropriate diluent and preparation method may differ by brand.

✔️ Safety Information:

• Thyroid, adrenal, pituitary, and other relevant endocrine disorders should be assessed and controlled before treatment.
• Ovarian response must be monitored regularly using ultrasound and estradiol measurements.
• Excessive ovarian stimulation may require stopping rFSH and withholding hCG to reduce the risk of ovarian hyperstimulation syndrome (OHSS).
• Women undergoing fertility treatment may have an increased risk of multiple pregnancy and ectopic pregnancy.
• Pregnancy loss may be more common following assisted reproductive procedures than in spontaneous pregnancies.
• The first injection should be administered under direct medical supervision.
• Although uncommon, severe allergic reactions may occur.
• In men, semen analysis is recommended during follow-up to evaluate treatment effectiveness.

✔️ Pregnancy & Lactation

rFSH must not be used during pregnancy or breastfeeding. Treatment should be initiated only after pregnancy has been excluded and the prescribing specialist has assessed the patient's suitability.

✔️ rFSH should not be used in patients with:

• Tumours of the ovaries, breasts, uterus, pituitary gland, or hypothalamus.
• Pregnancy or breastfeeding.
• Unexplained vaginal bleeding.
• Hypersensitivity to rFSH or any of its ingredients.
• Primary ovarian failure.
• Uterine fibroids that are incompatible with pregnancy.
• Primary testicular failure in men.

✔️ Administration of rFSH

In women without primary ovarian failure, rFSH treatment is commonly administered for approximately 7–12 days to stimulate ovarian follicle growth and maturation. Once adequate follicular development is confirmed, hCG may be administered to trigger ovulation or final egg maturation, according to the treatment plan.

✔️ Side Effects of rFSH

rFSH may cause ovarian overstimulation in women. Possible symptoms include pelvic or abdominal pain, bloating, nausea, vomiting, and sudden weight gain. Severe cases may lead to breathing difficulties, reduced urine output, fluid accumulation in the lungs, or blood clots.

Other serious warning signs include severe pelvic pain, chest pain, or significant breathing problems. Treatment may also increase the chance of multiple pregnancy, including twins or higher-order pregnancies.

✔️ Storage:

Store in a refrigerator at 2°C–8°C and do not freeze. Keep out of reach of children. Always follow the specific product packaging for storage requirements before and after reconstitution.